Bayer to build $2.2bn Ohio pharma campus

Bayer (BAYNd) plans to invest $2.2 billion to build a new pharmaceutical manufacturing campus in New Albany, Ohio, within the New Albany International Business Park. The company describes the project as a significant step to expand its manufacturing footprint in the United States and to support growth of its pharmaceuticals business in its largest market.

The campus is designed as a flexible, modular site that will integrate both drug-substance and drug-product manufacturing. This configuration is intended to support Bayer’s expanding portfolio in areas such as oncology, cardiovascular care and renal therapies.

The investment is projected to create about 600 permanent, high-paying jobs once the plant is fully operational. In addition, the construction phase is expected to generate roughly 1,500 construction jobs during the build-out period.

The campus will be located in a region that is developing its life-sciences workforce, and the project is expected to draw on local training initiatives, including efforts linked to the Ohio Life Science Training Center.

Bayer and state officials outlined a phased development plan for the New Albany site. The first module, focused on drug-substance manufacturing, is expected to become operational in 2031.

A second module dedicated to finished drug-product manufacturing is planned to follow in 2034. This staged approach is intended to bring capacity online over time while the broader campus build-out continues.

State and local officials, including Ohio Governor Mike DeWine and representatives of JobsOhio, joined Bayer in announcing the project. The company plans to pursue a Job Creation Tax Credit from the Ohio Department of Development as part of the investment package.

Bayer may also seek additional assistance from JobsOhio, with specific terms to be disclosed after a final agreement is executed. The involvement of state agencies underscores the role of public incentives in supporting the large-scale manufacturing investment.

Bayer frames the New Albany campus as a deliberate move to reinforce its U.S. manufacturing base. By adding advanced production capacity in Ohio, the company aims to better support its pharmaceutical portfolio in a key market.

The combination of substantial capital investment, job creation and long-dated operational targets positions the project as a central element of Bayer’s long-term U.S. pharmaceutical strategy.